---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-040038"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2026-06-03T11:03:09+00:00"
generated_at: "2026-06-03T11:05:22.495612+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics appoints Dr. Anna Greka to Board of Directors

## Summary
- Board increased to seven directors, effective June 15, 2026, with appointment of Anna Greka, M.D., Ph.D. as Class III director.
- Dr. Greka is Professor of Medicine at Harvard Medical School and Mass General Brigham, and holds leadership roles at Broad Institute.
- She will serve on Compensation Committee and Science and Technology Committee, receiving standard non-employee director compensation.
- Standard indemnification agreement entered; no related-party transactions disclosed.

## SEC filing metadata
- accession: 0001628280-26-040038
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2026-06-03T11:03:09+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828026040038/0001628280-26-040038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828026040038/ovid-20260602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-040038
- JSON: https://secwatch.observer/filing/0001628280-26-040038.json
- Plain text: https://secwatch.observer/filing/0001628280-26-040038.txt

## Key facts
- Executive change
  Anna Greka was appointed as Class III director at Ovid Therapeutics Inc..
  - Action: appointed
  - Role: Class III director
  source text: On May 29, 2026, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) approved, effective as of June 15, 2026, an increase in the size of the Board and, upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), the appointment of Anna Greka, M.D., Ph.D., as a Class III director of the Company, with her term expiring at the Company’s 2029 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000162828026040038/0001628280-26-040038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.